Cargando…

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited. With the exception of the commercialized CD19 CAR-T for hematolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Lichen, Yang, Xiaomei, Zhong, Dani, Xie, Shenxia, Shi, Wei, Li, Yangzi, Hou, Xiaoqiong, HuaYao, Zhou, Huihui, Zhao, Minlong, Ding, Ziqiang, Zhao, Xinyue, Mo, Fengzhen, Yin, Shihua, Liu, Aiqun, Lu, Xiaoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492946/ https://www.ncbi.nlm.nih.gov/pubmed/32964055 http://dx.doi.org/10.1155/2020/2454907

Ejemplares similares

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
por: Sun, Shuyang, et al.
Publicado: (2021)

Opportunities and Challenges for Antibodies against Intracellular Antigens
por: Yang, Xiaofeng, et al.
Publicado: (2019)

Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects
por: Xie, Shenxia, et al.
Publicado: (2021)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
por: Ding, Ziqiang, et al.
Publicado: (2023)

Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
por: Mo, Fengzhen, et al.
Publicado: (2021)

Highly sensitive detection of CTLA-4-positive T-cell subgroups based on nanobody and fluorescent carbon quantum dots
por: Wang, Wu, et al.
Publicado: (2019)

A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor
por: Sun, Shuyang, et al.
Publicado: (2023)

In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice
por: Ding, Ziqiang, et al.
Publicado: (2020)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
por: Poorebrahim, Mansour, et al.
Publicado: (2021)

Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
por: Teppert, Karin, et al.
Publicado: (2022)

Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers
por: Yang, Xiaomei, et al.
Publicado: (2019)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
por: Shevyrev, D. V., et al.
Publicado: (2022)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide
por: Lai, Chunhui, et al.
Publicado: (2018)

CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins
por: Jost, Christian, et al.
Publicado: (2020)

Challenges of CAR- and TCR-T cell–based therapy for chronic infections
por: Bertoletti, Antonio, et al.
Publicado: (2020)

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
por: Omer, Bilal, et al.
Publicado: (2022)

Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)
por: Ivica, Nikola A., et al.
Publicado: (2021)

TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens
por: Akatsuka, Yoshiki
Publicado: (2020)

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
por: Hiltensperger, Michael, et al.
Publicado: (2023)

Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022)

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
por: MacLeod, Daniel T., et al.
Publicado: (2017)

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
por: Wachsmann, Tassilo L. A., et al.
Publicado: (2022)

CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function
por: Sahillioglu, Ali Can, et al.
Publicado: (2021)

Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control
por: Cai, Yihua, et al.
Publicado: (2021)

Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4
por: Alsalloum, Alaa, et al.
Publicado: (2023)

Antibody-based binding domain fused to TCRγ chain facilitates T cell cytotoxicity for potent anti-tumor response
por: Chen, Zhao, et al.
Publicado: (2023)

Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance
por: Füchsl, Franziska, et al.
Publicado: (2022)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

Lck Domains Differentially Contribute to Pre–T Cell Receptor (Tcr)–And TCR-α/β–Regulated Developmental Transitions
por: Lin, Kui, et al.
Publicado: (2000)

Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain
por: Kuball, Jürgen, et al.
Publicado: (2009)

γδTCR immunoglobulin constant region domain exchange in human αβTCRs improves TCR pairing without altering TCR gene-modified T cell function
por: Tao, Changli, et al.
Publicado: (2017)

Domains of the TCR beta-chain required for early thymocyte development
Publicado: (1996)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products
por: Lu, Alex, et al.
Publicado: (2020)

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
por: Wang, Zhenguang, et al.
Publicado: (2021)

Innate-like NKp30(+)CD8(+) T cells armed with TCR/CAR target tumor heterogeneity
por: Correia, Margareta P., et al.
Publicado: (2021)

Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)
por: Cassioli, Chiara, et al.
Publicado: (2022)

Examining Variable Domain Orientations in Antigen Receptors Gives Insight into TCR-Like Antibody Design
por: Dunbar, James, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_65fnk9s63g4cjurptigh7mpt19